Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
about
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic InterventionsRecent advances and novel treatment paradigms in acute lymphocytic leukemiaClinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma.
P2860
Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
@en
type
label
Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
@en
prefLabel
Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
@en
P2860
P356
P1433
P1476
Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
@en
P2860
P304
P356
10.2217/FON.14.73
P407
P577
2014-05-01T00:00:00Z